Literature DB >> 26241578

Water-Soluble MMP-9 Inhibitor Reduces Lesion Volume after Severe Traumatic Brain Injury.

Mijoon Lee, Zhenzhou Chen1, Brittany N Tomlinson1, Major Gooyit, Dusan Hesek, María Raquel Juárez1, Rasheeq Nizam1, Bill Boggess, Elena Lastochkin, Valerie A Schroeder, William R Wolter, Mark A Suckow, Jiancun Cui1, Shahriar Mobashery, Zezong Gu1, Mayland Chang.   

Abstract

SB-3CT is a potent and selective inhibitor of matrix metalloproteinase (MMP)-2 and -9, which has shown efficacy in an animal model of severe traumatic brain injury (TBI). However, SB-3CT is poorly water-soluble and is metabolized primarily to p-hydroxy SB-3CT (2), a more potent inhibitor than SB-3CT. We synthesized the O-phosphate prodrug (3) of compound 2 to enhance its water solubility by more than 2000-fold. The prodrug 3 was a poor MMP inhibitor, but readily hydrolyzed to the active 2 in human blood. Pharmacokinetics and brain distribution studies in mice showed that 2 crossed the blood-brain barrier (BBB) and achieved therapeutic concentrations in the brain. The prodrug 3/compound 2 was evaluated in a mouse model of severe TBI and found to significantly decrease the brain lesion volume and improve neurological outcomes. MMP-9 inhibition by a water-soluble thiirane inhibitor is a promising therapy for treatment of TBI.

Entities:  

Keywords:  MMP-9; brain distribution; prodrug; traumatic brain injury

Mesh:

Substances:

Year:  2015        PMID: 26241578      PMCID: PMC5800744          DOI: 10.1021/acschemneuro.5b00140

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN: 1948-7193            Impact factor:   4.418


  18 in total

Review 1.  The blood-brain barrier: bottleneck in brain drug development.

Authors:  William M Pardridge
Journal:  NeuroRx       Date:  2005-01

2.  Effects of matrix metalloproteinase-9 gene knock-out on morphological and motor outcomes after traumatic brain injury.

Authors:  X Wang; J Jung; M Asahi; W Chwang; L Russo; M A Moskowitz; C E Dixon; M E Fini; E H Lo
Journal:  J Neurosci       Date:  2000-09-15       Impact factor: 6.167

3.  Potent mechanism-based inhibitors for matrix metalloproteinases.

Authors:  Masahiro Ikejiri; M Margarida Bernardo; R Daniel Bonfil; Marta Toth; Mayland Chang; Rafael Fridman; Shahriar Mobashery
Journal:  J Biol Chem       Date:  2005-07-26       Impact factor: 5.157

4.  Spatial learning and memory impairment and increased locomotion in a transgenic amyloid precursor protein mouse model of Alzheimer's disease.

Authors:  J M Walker; S W Fowler; D K Miller; A Y Sun; G A Weisman; W G Wood; G Y Sun; A Simonyi; T R Schachtman
Journal:  Behav Brain Res       Date:  2011-04-01       Impact factor: 3.332

5.  Sulfonate-containing thiiranes as selective gelatinase inhibitors.

Authors:  Sebastian A Testero; Mijoon Lee; Rachel T Staran; Mana Espahbodi; Leticia I Llarrull; Marta Toth; Shahriar Mobashery; Mayland Chang
Journal:  ACS Med Chem Lett       Date:  2010-12-13       Impact factor: 4.345

6.  Kinetic analysis of the binding of human matrix metalloproteinase-2 and -9 to tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2.

Authors:  M W Olson; D C Gervasi; S Mobashery; R Fridman
Journal:  J Biol Chem       Date:  1997-11-21       Impact factor: 5.157

7.  Metabolism of a highly selective gelatinase inhibitor generates active metabolite.

Authors:  Mijoon Lee; Adriel Villegas-Estrada; Giuseppe Celenza; Bill Boggess; Marta Toth; Gloria Kreitinger; Christopher Forbes; Rafael Fridman; Shahriar Mobashery; Mayland Chang
Journal:  Chem Biol Drug Des       Date:  2007-10-10       Impact factor: 2.817

8.  A potent gelatinase inhibitor with anti-tumor-invasive activity and its metabolic disposition.

Authors:  Mijoon Lee; Giuseppe Celenza; Bill Boggess; Jennifer Blase; Qicun Shi; Marta Toth; M Margarida Bernardo; William R Wolter; Mark A Suckow; Dusan Hesek; Bruce C Noll; Rafael Fridman; Shahriar Mobashery; Mayland Chang
Journal:  Chem Biol Drug Des       Date:  2009-02       Impact factor: 2.817

9.  Active site ring-opening of a thiirane moiety and picomolar inhibition of gelatinases.

Authors:  Christopher Forbes; Qicun Shi; Jed F Fisher; Mijoon Lee; Dusan Hesek; Leticia I Llarrull; Marta Toth; Michael Gossing; Rafael Fridman; Shahriar Mobashery
Journal:  Chem Biol Drug Des       Date:  2009-10-06       Impact factor: 2.817

10.  Selective inhibition of matrix metalloproteinase-9 attenuates secondary damage resulting from severe traumatic brain injury.

Authors:  Orr Hadass; Brittany N Tomlinson; Major Gooyit; Shanyan Chen; Justin J Purdy; Jennifer M Walker; Chunyang Zhang; Andrew B Giritharan; Whitley Purnell; Christopher R Robinson; Dmitriy Shin; Valerie A Schroeder; Mark A Suckow; Agnes Simonyi; Grace Y Sun; Shahriar Mobashery; Jiankun Cui; Mayland Chang; Zezong Gu
Journal:  PLoS One       Date:  2013-10-23       Impact factor: 3.240

View more
  9 in total

1.  Exploitation of Conformational Dynamics in Imparting Selective Inhibition for Related Matrix Metalloproteinases.

Authors:  Kiran V Mahasenan; Maria Bastian; Ming Gao; Emma Frost; Derong Ding; Katerina Zorina-Lichtenwalter; John Jacobs; Mark A Suckow; Valerie A Schroeder; William R Wolter; Mayland Chang; Shahriar Mobashery
Journal:  ACS Med Chem Lett       Date:  2017-05-01       Impact factor: 4.345

2.  Design, Synthesis and Biological Evaluation of Prodrugs of 666-15 as Inhibitors of CREB-Mediated Gene Transcription.

Authors:  Jiangling Peng; Mark Miller; Bingbing X Li; Xiangshu Xiao
Journal:  ACS Med Chem Lett       Date:  2022-02-17       Impact factor: 4.632

Review 3.  Early to Long-Term Alterations of CNS Barriers After Traumatic Brain Injury: Considerations for Drug Development.

Authors:  Beatriz Rodriguez-Grande; Aleksandra Ichkova; Sighild Lemarchant; Jerome Badaut
Journal:  AAPS J       Date:  2017-09-13       Impact factor: 4.009

Review 4.  Neurovascular dysfunction and neurodegeneration in dementia and Alzheimer's disease.

Authors:  Amy R Nelson; Melanie D Sweeney; Abhay P Sagare; Berislav V Zlokovic
Journal:  Biochim Biophys Acta       Date:  2015-12-17

Review 5.  Extracellular matrix and traumatic brain injury.

Authors:  Naijil George; Herbert M Geller
Journal:  J Neurosci Res       Date:  2018-01-18       Impact factor: 4.164

Review 6.  Blood-Brain Barrier Mechanisms in Stroke and Trauma.

Authors:  Wenlu Li; Fang Cao; Hajime Takase; Ken Arai; Eng H Lo; Josephine Lok
Journal:  Handb Exp Pharmacol       Date:  2022

7.  Inhibition of Matrix Metalloproteinase 9 Enhances Rod Survival in the S334ter-line3 Retinitis Pigmentosa Model.

Authors:  Jung-A Shin; Hwa Sun Kim; Andrew Vargas; Wan-Qing Yu; Yun Sung Eom; Cheryl Mae Craft; Eun-Jin Lee
Journal:  PLoS One       Date:  2016-11-28       Impact factor: 3.240

Review 8.  The Prodrug Approach: A Successful Tool for Improving Drug Solubility.

Authors:  Daniela Hartmann Jornada; Guilherme Felipe dos Santos Fernandes; Diego Eidy Chiba; Thais Regina Ferreira de Melo; Jean Leandro dos Santos; Man Chin Chung
Journal:  Molecules       Date:  2015-12-29       Impact factor: 4.411

Review 9.  Mechanisms of Action of Novel Drugs Targeting Angiogenesis-Promoting Matrix Metalloproteinases.

Authors:  Gregg B Fields
Journal:  Front Immunol       Date:  2019-06-04       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.